Agilent Technologies says changes in the industry this year will present opportunities for continued growth in its pharma processing equipment and consumables business.
Agilent Technologies has inked a deal to acquire Seahorse Bioscience, adding a cell metabolism analysis platform to its lead development and preclinical offerings.
Agilent Technologies has continued its push into the materials
science market with the acquisition of nanoindentation instrument
manufacturer Nano Instruments.
Agilent Technologies has licensed BIA Separations' bio-monolithic
technology and intends to use it in the commercialisation of
analytical high performance liquid chromatography (HPLC)
bio-monolith columns.
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
Agilent Technologies has signed an agreement with Groton Biosystems
to co-market measuring solutions for the pharmaceutical industry,
as the Process Analytical Technology (PAT) initiative gains
popularity among drug manufacturers...
Agilent Technologies has chosen Distek to be its number-one
provider for dissolution instrumentation service in North America
under its Lab Resource Management (LRM) programme.
Agilent Technologies has introduced its new microarray that offers
high-resolution genomic coverage, whilst enabling multiple
experiments per slide. The technology has the potential to make
savings both in time and cost.
Agilent Technologies has stepped out of its comfort zone to pursue
a new line of business in ribonucleic acid (RNA) production, with
the recent acquisition of SynPro.
Agilent Technologies launches its latest microarray solution for
analysing activity at regulatory regions of genomes, enabling
researchers to examine gene regulation in a more efficient and
cost-effective manner.
Agilent Technologies introduces a high-capacity human protein
removal system for proteomics research, that removes up to 99 per
cent of the six most common proteins from human blood serum.
Agilent Technologies has launched what it says is the industry's
first gas chromatograph/mass spectrometer (GC/MS) system with a
user interface that allows the electronic sharing of application
methods.
A hive of activity at Agilent Technologies has trnsformed the
company into a significant player in the competitive microarray
platform market with the expansion of its array-based genomics,
disease research and drug R&D applications.
Agilent Technologies has launched what it claims is the industry's
first fully automated, high-throughput 'lab-on-a-chip system' for
basic life science research and drug discovery. The Agilent 5100
Automated provides...
Agilent Technologies has launched a software package to help drug
companies keep a close eye on the quality of chemical compounds.
The firm says the product is the first of its kind, allowing a more
than seven-fold increase in the...
Agilent returns to profit for the first time in two years in the
fourth quarter ended October 31, as cost-cutting compensated for a
modest decline in revenues.
